Glioblastoma is the most common and aggressive type of primary brain tumor, with an average survival rate of 15 months, ...

In a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall ...

A recent study has revealed that chloride flow through channels on the surface of tumor cell lines plays a crucial role in ...

The agent is currently being evaluated in a phase 1a study, and a phase 1b/2a study will continue to assess LP-184’s safety ...

Chloride ion flows that enter the cells play an important role in the duplication of glioblastoma cells, a highly aggressive ...

Shilpa Medicare's drug is presently undergoing a Phase 1A clinical trial to test its safety and how well it is tolerated in ...

Glioblastoma Treatment Drugs MarketThe glioblastoma treatment drugs market is poised for substantial growth, with a projected valuation of approximately USD 756.1 million in 2023. The market is ...

Brussels, Belgium, 8 October 2024. A groundbreaking study1 led by Dr Monika E. Hegi, MD, PhD and European Organisation for ...

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and ...

Glioblastoma (GBM) is the most lethal brain tumor, with a median survival rate of merely 12-16 months after diagnosis.

For patients with glioblastoma imaged daily with magnetic resonance imaging (MRI)-linear accelerator (linac) throughou ...

Funding secures ongoing pipeline progress and achievement of preclinical and clinical milestones Oral small molecule INV501: collaboration with ...